within Pharmacolibrary.Drugs.S_SensoryOrgans.S03B_Corticosteroids.S03BA03_Betamethasone;

model Betamethasone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.238888888888889e-06,
    adminDuration = 600,
    adminMass = 7 / 1000000,
    adminCount = 1,
    Vd = 0.0018700000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0030499999999999998,
    k12 = 3.0138888888888886e-06,
    k21 = 3.0138888888888886e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Betamethasone</td></tr><tr><td>ATC code:</td><td>S03BA03</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>7</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.87</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.218</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Betamethasone is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties. It is used in the treatment of various inflammatory, allergic, and autoimmune disorders. It is approved and widely used in contemporary medicine, including formulations for ophthalmic, topical, and systemic use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single intramuscular (IM) administration of betamethasone phosphate/betamethasone acetate combination.</p><h4>References</h4><ol><li><p>Schoenmakers, S, et al., &amp; Koch, BCP (2025). Pharmacokinetics of betamethasone in pre-eclampsia: An in vivo and ex vivo study. <i>British journal of clinical pharmacology</i> None –. DOI:<a href=\"https://doi.org/10.1002/bcp.70035\">10.1002/bcp.70035</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40083164/\">https://pubmed.ncbi.nlm.nih.gov/40083164</a></p></li><li><p>Krzyzanski, W, et al., &amp; Jusko, WJ (2021). Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. <i>Journal of pharmacokinetics and pharmacodynamics</i> 48(2) 261–272. DOI:<a href=\"https://doi.org/10.1007/s10928-020-09730-z\">10.1007/s10928-020-09730-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33389521/\">https://pubmed.ncbi.nlm.nih.gov/33389521</a></p></li><li><p>Krzyzanski, W, et al., &amp; Jusko, WJ (2021). Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women. <i>Journal of pharmacokinetics and pharmacodynamics</i> 48(3) 411–438. DOI:<a href=\"https://doi.org/10.1007/s10928-021-09755-y\">10.1007/s10928-021-09755-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33954911/\">https://pubmed.ncbi.nlm.nih.gov/33954911</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S03BA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Betamethasone;
